Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24423522 | 1.00 | MAPK1 (0.63) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL13783322 | 0.93 | MAPK1 (0.53) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL20159607 | 0.89 | L3MBTL1 (0.51) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL24424685 | 0.86 | EPHX2 (0.48) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL13746318 | 0.85 | GAA (0.61) | MAPK1ALDH1A1EPHX2GAAL3MBTL1 | |
| SCHEMBL10265288 | 0.85 | POLB (0.53) | MAPK1ALDH1A1RAB9AEPHX2GAA | |
| SCHEMBL7159674 | 0.85 | MAPK1 (0.60) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL7159673 | 0.85 | MAPK1 (0.60) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL517408 | 0.85 | MAPK1 (0.60) | MAPK1ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL14985440 | 0.85 | MAPK1 (0.60) | MAPK1ALDH1A1NPC1RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | MAPK1 383/4885ALDH1A1 2000/4885NPC1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.